Lv5
1270 积分 2024-08-08 加入
Lifestyle‐associated serum metabolites profiling in relation to risk of late‐onset psoriasis
8天前
已完结
Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis
12天前
已完结
Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis
26天前
已关闭
Interleukin‐23 inhibitors demonstrate high effectiveness in the treatment of a real‐world cohort of 82 psoriatic patients regardless of the HLA‐Cw6 status
26天前
已完结
[Chinese expert consensus on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors]
1个月前
已完结
Patient-Centred Perspectives – Empowerment, Engagement, and the Future of Cardiovascular Prevention in Psoriasis
1个月前
已完结
IL-23 inhibition for chronic inflammatory disease
2个月前
已完结
Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease
2个月前
已完结
Global Psoriasis Burden and Forecasts to 2050
2个月前
已关闭
62641 Treatment patterns, drug survival, and effectiveness of tildrakizumab among patients with prior interleukin-17 experience in the CorEvitas Psoriasis Registry
3个月前
已完结
皖公网安备34019202002308
